// App-Quantinova.ai

7075 : CDA status as predictive marker of aplasia duration and clinical outcome in AML patients receiving cytarabine based chemotherapy.

Researchers

Presenter

  • Cedric Mercier

Principal Investigators

  • Raphaelle Fanciullino

  • Gerard Sebahoun

  • Joseph Ciccolini

  • Regis Costello

  • Julien Colle

  • Geoffroy Venton

  • Vadim Ivanov

Medical Centers

  • La Conception University Hospital, Marseille, France, Marseille, France

  • Transfert Oncology Laboratory, Nord University Hospital of Marseille, Marseille, FranceLa Conception University Hospital of Marseille, Marseille, FranceHopital Nord, Marseilles, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Alpha-thalassemia myelodysplasia syndrome

Biomarkers

  • 18F-fluorodeoxyglucose

  • Circulating tumor cells

  • Cytidine deaminase

Drug/Treatment

  • Cytarabine liposomal

Outcome

  • N/A

Study Design

  • observational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved